Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.23 USD
Change Today -0.0049 / -2.09%
Volume 34.7K
As of 8:10 PM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

aeolus pharmaceuticals inc (AOLS) Snapshot

Open
$0.24
Previous Close
$0.24
Day High
$0.26
Day Low
$0.23
52 Week High
09/2/14 - $0.55
52 Week Low
10/8/14 - $0.19
Market Cap
31.3M
Average Volume 10 Days
20.8K
EPS TTM
$-0.04
Shares Outstanding
135.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AEOLUS PHARMACEUTICALS INC (AOLS)

Related News

No related news articles were found.

aeolus pharmaceuticals inc (AOLS) Related Businessweek News

No Related Businessweek News Found

aeolus pharmaceuticals inc (AOLS) Details

Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops of a platform of novel compounds in biodefense, oncology, and pulmonary disorders. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound, AEOL 10150, which has completed 2 Phase I clinical trials is developed against the pulmonary sub-syndrome of acute radiation syndrome, as well as for the hematopoetic sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants, such as chlorine gas, sulfur mustard gas, phosgene gas, and nerve agents. The company is also developing AEOL 11207, AEOL 1114B, and AEOL 11203 for the treatment of epilepsy and Parkinson’s disease. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.

4 Employees
Last Reported Date: 02/13/15
Founded in 1994

aeolus pharmaceuticals inc (AOLS) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: $433.9K
Chairman of The Board, Chief Financial Office...
Total Annual Compensation: $352.6K
Compensation as of Fiscal Year 2014.

aeolus pharmaceuticals inc (AOLS) Key Developments

Aeolus Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2015

Aeolus Pharmaceuticals Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended June 30, 2015. For the quarter, the company reported contract contract revenues of $63,000 compared with $4,983,000 for the same period last year. Loss from operations was $784,000 compared with income from operations of $1,576,000 for the same period last year. Net loss was $784,000 or $0.01 diluted per share compared with net income of $1,576,000 or $0.01 diluted per share for the same period last year. For the nine months, the company reported contract revenue of $2,177,000 compared with $7,214,000 for the same period last year. Loss from operations was $2,194,000 compared with income from operations of $445,000 for the same period last year. Net loss was $2,194,000 or $0.02 diluted per share compared with net income of $445,000 or $0.00 diluted per share for the same period last year. Net cash used in operating activities was $1,121,000 compared with cash generated from operating activities of $403,000 for the same period last year.

Barda Exercises $3 Million in Additional Contract Funding for Development of Aeol 10150 as Treatment for Acute Radiation Syndrome

Aeolus Pharmaceuticals Inc. announced that the Biomedical Advanced Research and Development Authority (BARDA) exercised $3 million in additional contract options under its advanced research and development contract for AEOL 10150. BARDA is a division of the U.S. Department of Health and Human Services that manages the advanced development and purchase of medical countermeasures for public health threats. Aeolus is developing its lead compound, AEOL 10150, as a treatment for the pulmonary syndrome of Acute Radiation Syndrome (Lung-ARS) and delayed effects of acute radiation exposure (DEARE) under a contract with BARDA worth up to $118 million. The contract is designed to produce the data necessary for an approval under the FDA "Animal Rule" and for a pre-Emergency Use Authorization (EUA) filing. An approval or pre-EUA would allow the federal government to buy AEOL 10150 for the Strategic National Stockpile under the Pandemic All-Hazards Preparedness Reauthorization Act (PAHPRA). PAHPRA is designed to accelerate the research, development, purchase and availability of effective medical countermeasures for the Strategic National Stockpile.

Aeolus Pharmaceuticals Inc. Reports Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended March 31, 2015

Aeolus Pharmaceuticals Inc. reported consolidated unaudited earnings results for the second quarter and six months ended March 31, 2015. For the quarter, the company reported contract revenue of $1,189,000 compared with $1,438,000 for the same period last year. Loss from operations was $712,000 compared with $437,000 for the same period last year. Net loss was $712,000 or $0.01 diluted per share compared with $437,000 for the same period last year. For the six months, the company reported contract revenue of $2,114,000 compared with $2,231,000 for the same period last year. Loss from operations was $1,410,000 compared with $1,132,000 for the same period last year. Net loss was $1,410,000 or $0.01 diluted per share compared with $1,132,000 or $0.01 diluted per share for the same period last year. Net cash used in operating activities was $1,269,000 compared with $349,000 for the same period last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AOLS:US $0.23 USD -0.0049

AOLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AOLS.
View Industry Companies
 

Industry Analysis

AOLS

Industry Average

Valuation AOLS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AEOLUS PHARMACEUTICALS INC, please visit www.aeoluspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.